Multiple Sclerosis (MS) Treatment Insurance Denial Appeal — Free AI Letter
Multiple sclerosis treatment is dominated by high-cost specialty disease-modifying therapies (DMTs), which are among the most heavily managed drugs in commercial insurance. Insurers commonly require step therapy that conflicts with neurologist treatment recommendations, deny prior authorization for newer or higher-efficacy agents, impose continued-authorization criteria that don't align with MS disease course, and deny MRI surveillance imaging used to track disease activity. The clinical landscape has shifted significantly over the past decade toward earlier and higher-efficacy treatment - the AAN, ECTRIMS, and ACTRIMS now generally recommend an early high-efficacy approach for many patients with relapsing MS, particularly those with high disease activity, instead of the older 'escalation' model that started with safer but less effective agents. Successful appeals document the specific MS disease course, prior treatment history if any, neurologist's clinical reasoning for the specific DMT, and citation to current AAN guidelines or peer-reviewed evidence supporting the high-efficacy approach.
Why insurers deny Multiple Sclerosis claims
The laws that help you appeal
Most states have step therapy reform laws that require insurers to grant exceptions when (a) the required drug is contraindicated for the patient, (b) the patient has previously tried and failed the required drug on this or another insurer, (c) the required drug is expected to be ineffective based on clinical characteristics, or (d) the required drug will cause adverse interactions. As of 2026, step therapy reform laws exist in over 30 states, though specifics vary. Cite your state's law in any step therapy appeal. The Affordable Care Act, 42 USC 18022, includes prescription drugs as an essential health benefit and 45 CFR 156.122 requires plans to cover at least one drug per US Pharmacopeia category and class - though specific drug coverage within a class can be limited. ERISA, 29 USC 1132, provides procedural appeal rights. Federal external review rights under 45 CFR 147.136 apply. State insurance code typically requires medical-necessity determinations to follow generally accepted standards of medical practice, which for MS includes the AAN Practice Guidelines on Disease-Modifying Therapies in MS (most recently updated as a 2018 evidence-based guideline with subsequent amendments) and the National Multiple Sclerosis Society's clinical recommendations.
Evidence to include in your appeal
- Letter of medical necessity from your treating neurologist (preferably an MS specialist) documenting the type of MS (relapsing-remitting, secondary progressive, primary progressive, clinically isolated syndrome), disease activity (relapse frequency, MRI lesion burden, EDSS score), prior DMTs tried with response and tolerability, and clinical rationale for the specific DMT requested
- Recent MRI imaging reports showing active disease (new T2 lesions, gadolinium-enhancing lesions, brain or spinal cord atrophy)
- Citation to the AAN Practice Guideline on DMTs in MS supporting the requested agent for the patient's disease course
- If step therapy is at issue, citation to the specific state step therapy reform law and documentation of which exception criterion applies
- Documentation of comorbidities, JC virus serology (relevant for Tysabri), pregnancy plans (relevant for several agents), and other patient-specific factors driving DMT selection
- If continued therapy denial is at issue, comparison of current MRI to baseline showing disease control, with explicit explanation that stable MRI on therapy does not mean the therapy is no longer needed
- For specialty agents, prescriber NMSS Center for MS Care affiliation if applicable, and documentation that the prescribing physician is following the FDA-approved REMS protocol where applicable
Winning strategy
Lead with the neurologist's specific clinical rationale tied to the patient's disease characteristics. Generic 'we want this drug' arguments will not survive specialty drug review. For step therapy denials, identify which state law exception applies and document the underlying clinical fact specifically - 'patient has tried and failed glatiramer acetate with documented relapses' is much stronger than 'older drugs aren't preferred.' For high-efficacy agent denials, cite the shift in MS treatment paradigm reflected in current AAN guidance and the peer-reviewed evidence supporting earlier high-efficacy treatment for patients with high disease activity. For continued-authorization denials based on stable MRI, frame stable MRI as evidence the therapy is working, not evidence the therapy is unnecessary - this is one of the most common and most appealable patterns. Always request that the appeal reviewer be a board-certified neurologist with MS expertise. For ERISA self-funded plans, ensure the administrative record is complete because federal court review under 29 USC 1132 is limited to the record before the plan administrator. Coordinate with the prescribing neurologist's office, which typically has experience with the specific specialty pharmacy benefit manager handling the case.
Relevant treatments and medications
Generate your Multiple Sclerosis appeal letter
Upload your denial notice or EOB. Our 5-agent AI pipeline drafts a professional appeal in about 2 minutes, free.
Upload my denial · Free